Skip to main content

Table 4 Total additional expense of the Biovac Institute via PAHO excluding premium (US$ million)

From: An evaluation of South Africa’s public–private partnership for the localisation of vaccine research, manufacture and distribution

Vaccine Type

2010

2011

2012

2013

2014

Total

TT

N/A

N/A

N/A

N/A

N/A

N/A

HBV Adult

0.128

0.164

0.171

0.161

0.057

0.679

HBV Paediatric

0.654

1.118

1.111

0.957

0.190

4.030

OPV

0.009

0.357

1.185

0.775

0.448

2.774

Measles/MMR

1.011

1.940

2.996

2.654

2.911

11.513

BCG

−0.052

0.148

0.208

0.464

−0.071

0.697

Td

1.180

1.711

1.756

1.911

0.903

7.461

PCV

14.460

31.290

24.565

8.755

−0.886

78.184

Rota

−0.611

1.917

3.157

3.687

−1.344

6.805

Pentavalent

18.164

32.010

41.175

18.026

−1.678

107.697

HPV

0.000

0.000

0.000

0.000

−0.244

−0.244

Total

34.94

70.66

76.32

37.39

0.29

219.60

  1. BCG Bacillus Calmette–Guérin, HBV hepatitis B, HPV human papillomavirus, MMR measles, mumps and rubella, OPV oral poliovirus, PCV Pneumococcal conjugate vaccine, Rota rotavirus vaccine, Td tetanus diphtheria, TT tetanus toxoid